首页> 美国卫生研究院文献>Scientific Reports >AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins
【2h】

AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins

机译:AKT1和AKT2亚型在乳腺癌进展过程中通过调节特定的下游蛋白发挥不同的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of this study was to elucidate the mechanisms associated with the specific effects of AKT1 and AKT2 isoforms in breast cancer progression. We modulated the abundance of specific AKT isoforms in IBH-6 and T47D human breast cancer cell lines and showed that AKT1 promoted cell proliferation, through S6 and cyclin D1 upregulation, but it inhibited cell migration and invasion through β1-integrin and focal adhesion kinase (FAK) downregulation. In contrast, AKT2 promoted cell migration and invasion through F-actin and vimentin induction. Thus, while overexpression of AKT1 promoted local tumor growth, downregulation of AKT1 or overexpression of AKT2 promoted peritumoral invasion and lung metastasis. Furthermore, we evaluated The Cancer Genome Atlas (TCGA) dataset for invasive breast carcinomas and found that increased AKT2 but not AKT1 mRNA levels correlated with a worse clinical outcome. We conclude that AKT isoforms play specific roles in different steps of breast cancer progression, with AKT1 involved in the local tumor growth and AKT2 involved in the distant tumor dissemination, having AKT2 a poorer prognostic value and consequently being a worthwhile target for therapy.
机译:这项研究的目的是阐明与AKT1和AKT2亚型在乳腺癌进展中的特定作用相关的机制。我们调节了IBH-6和T47D人乳腺癌细胞系中特定AKT亚型的丰度,并显示AKT1通过S6和cyclin D1上调促进了细胞增殖,但通过β1-整合素和黏着斑激酶抑制了细胞迁移和侵袭( FAK)下调。相反,AKT2通过F-肌动蛋白和波形蛋白的诱导促进细胞迁移和侵袭。因此,虽然AKT1的过表达促进了局部肿瘤的生长,但是AKT1的下调或AKT2的过表达促进了肿瘤的浸润和肺转移。此外,我们评估了浸润性乳腺癌的癌症基因组图谱(TCGA)数据集,发现增加的AKT2而不是AKT1 mRNA水平与较差的临床预后相关。我们得出的结论是,AKT亚型在乳腺癌进展的不同步骤中发挥特定作用,其中AKT1参与局部肿瘤的生长,而AKT2参与远处的肿瘤的传播,AKT2的预后价值较差,因此成为治疗的有价值目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号